97 related articles for article (PubMed ID: 16029294)
1. An alternative cost effectiveness analysis of ThinPrep in the Australian setting.
Neville AM; Quinn MA
Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):289-94. PubMed ID: 16029294
[TBL] [Abstract][Full Text] [Related]
2. Modeling cost-effectiveness of cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
[TBL] [Abstract][Full Text] [Related]
3. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
5. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
[TBL] [Abstract][Full Text] [Related]
6. Cost of screening for cancerous and precancerous lesions of the cervix.
Méréa E; Le Galès C; Cochand-Priollet B; Cartier I; de Crémoux P; Vacher-Lavenu MC; Vielh P; Coste J
Diagn Cytopathol; 2002 Oct; 27(4):251-7. PubMed ID: 12357505
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
8. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
12. Liquid-based cytology can improve efficiency of cervical smear readers: evidence from timing surveys in two NHS cytology laboratories.
Dowie R; Stoykova B; Crawford D; Desai M; Mather J; Morgan K; Shirt M
Cytopathology; 2006 Apr; 17(2):65-72. PubMed ID: 16548990
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
Hutchinson ML; Berger BM; Farber FL
Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
Koong SL; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
[TBL] [Abstract][Full Text] [Related]
15. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
Perovic S
J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
[TBL] [Abstract][Full Text] [Related]
17. ["Cost-effectiveness" of cervical screening].
Kostova P
Akush Ginekol (Sofiia); 2007; 46(6):32-4. PubMed ID: 17974169
[TBL] [Abstract][Full Text] [Related]
18. Willingness to pay for new Papanicolaou test technologies.
Raab SS; Grzybicki DM; Hart AR; Kiely S; Andrew-JaJa C; Scioscia E
Am J Clin Pathol; 2002 Apr; 117(4):524-33. PubMed ID: 11939725
[TBL] [Abstract][Full Text] [Related]
19. Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: the case for remotely assisted radical prostatectomy.
O'Malley SP; Jordan E
Int J Technol Assess Health Care; 2007; 23(2):286-91. PubMed ID: 17493316
[TBL] [Abstract][Full Text] [Related]
20. Liquid-based cytology for cervical cancer screening.
Bentz JS
Expert Rev Mol Diagn; 2005 Nov; 5(6):857-71. PubMed ID: 16255628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
